| Submission declined on 8 December 2024 by Timtrent (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: I have applied WP:MOSHEAD for you. Please comply with all MOS items. The honorific "Dr" should not appear every time Kales is mentioned. 🇺🇦 FiddleTimtrent FaddleTalk to me 🇺🇦 18:27, 8 December 2024 (UTC)
- Comment: Please read and apply WP:REFB and WP:CITE. While offline references are "useful" you live and work in the days of the internet. Please use the correct citation templates and provide links to online versions were these are available. This will hasten a review. No reviewer is going to go a-hunting for the references fore a living perosn. 🇺🇦 FiddleTimtrent FaddleTalk to me 🇺🇦 18:13, 8 December 2024 (UTC)
- Comment: One reference only, for all these facts?You have confused Wikipedia with a website that is interested in your life and achievements. Please use a resume site like LinkedIn, and note WP:NOTLINKEDIN 🇺🇦 FiddleTimtrent FaddleTalk to me 🇺🇦 17:41, 8 December 2024 (UTC)
 | This biographical article is written like a résumé. |
 | This article is an autobiography or has been extensively edited by the subject or by someone connected to the subject. |
Helen C. Kales (born 15 March 1965), is the Joe P. Tupin Professor and Chair of Psychiatry and Behavioral Sciences At University of California Davis.[1] who is an internationally recognized expert in geriatric psychiatry,[2] with a particular focus on later-life depression, the use[3] and risks[4][5] of psychotropic medications for older adults, and improving dementia care.[6]
A fellowship-trained, board-certified geriatric psychiatrist, she is currently Chair of the Department of Psychiatry and Behavioral Sciences at the University of California, Davis (UC Davis), where she has served since 2019.[citation needed] Kales has authored over 170 peer-reviewed papers and 18 book chapters, with a research program grounded in her clinical work. She has been continuously funded by federal grants since 2004,[citation needed] serving as principal investigator on 11 major grants.[citation needed]
Education
editHelen (Eleni) Christine Kales was born on 15 March 1965 in Santa Monica California[citation needed] to Anthony and Joyce Kales. Her parents, both the first in their families to attend college, were completing training in Psychiatry at UCLA's Neuropsychiatric Institute and the West Los Angeles VA respectively.[relevant?] In 1972, Kales moved to Hershey Pennsylvania where her father had become Chair of Psychiatry at the Pennsylvania State University and became one of the founders of the field of Sleep Medicine.[7][8] She attended Hershey High School graduating in 1983,[citation needed] followed by Bucknell University where she earned a BA in Spanish Language and Literature with a minor in Biochemistry,[citation needed] graduating Summa Cum Laude in 1987. This was followed by a medical doctorate (MD) from the University of Rochester School of Medicine in Rochester New York in 1992[citation needed] and an internship and residency at the University of Michigan in Ann Arbor Michigan.[citation needed] Kales completed a 2-year geriatric psychiatry clinical and research fellowship in 1998.[where?][citation needed]
Career Overview
editKales is recognized for her work on improving outcomes for older adults with mental health conditions, including dementia and depression.[9][10] Her research also examines the use of and risks associated with antipsychotic and other psychotropic medications in older patients.[11][12] As a leader[citation needed] in dementia care research, she has contributed to international initiatives, including her direction of an international consensus panel on assessment and management of behavioral and psychological symptoms of dementia and appointment to the standing Lancet Global Commission on Dementia Prevention Intervention and Care, both in 2015.[13][14][15]
With an H-index of 62 and more than 26,000 citations as of 2024, Kales' contributions to the field have earned her national and international recognition[by whom?].[citation needed]
In addition to her extensive research work, Kales is a dedicated educator and mentor, guiding many junior faculty, fellows, and students in their academic careers. She is known for her leadership within the academic community and has served as a mentor to several faculty members with career development awards from the National Institute on Aging (NIA).[citation needed]
Administrative Experience
edit |
Chair, Department of Psychiatry and Behavioral Sciences (2019-present)m of University of California, Davis. As Chair, Kales oversees the department's mission, which includes clinical care, research, education, and service. The department employs over 500 individuals, including more than 100 faculty, and has a budget of $50 million annually. Under her leadership, the department has made significant strides, including:
- Recruiting over 30 faculty members, including 10 underrepresented minority faculty, in five years.
- Increasing diversity among trainees by 65% and achieving a top-15 ranking for the Psychiatry Residency Program in U.S. News & World Report.
- Restructuring the psychiatric emergency department, reducing patient "boarding" by two-thirds.
- Expanding outpatient mental health access and establishing new interdisciplinary services, such as an aging clinic and substance-use disorder treatment programs.
Selected Honors and Awards
edit| |
Kales has received numerous prestigious[peacock prose] awards throughout her career, including:
- Geriatric Psychiatry Research Award (2021), American College of Psychiatrists
- Mentor recognition at the NIMH Advanced Research Institute in Geriatric Mental Health
- Junior Investigator Award, American Association for Geriatric Psychiatry
- Named Expert Commissioner for the Lancet Global Commission on Dementia Prevention, Intervention, and Care
Mentoring and Teaching Leadership Activities
Mentoring Experience
edit| |
Kales has mentored numerous individuals, from undergraduate students to junior faculty. She has served as a primary mentor to multiple postdoctoral fellows and has helped several junior faculty members secure NIA career development funding. She has also taught courses at the undergraduate and graduate levels and has served as Co-Course Director in medical education programs.
Scholarly Leadership and Contributions
edit| |
- Over 170 peer-reviewed publications and 18 book chapters.
- Two streams of intellectual property related to dementia care in various stages of commercialization.
- Editorial roles with journals such as the American Journal of Geriatric Psychiatry and International Psychogeriatrics.
- International invited speaker at conferences in Vancouver, Toronto, London, and Berlin, among others.
- National and international grant reviewer for organizations such as the National Institute on Aging (NIA), the National Institute of Mental Health (NIMH), and the Alzheimer's Society (UK).
Grant Awards Summary
edit| |
Kales has secured more than $6 million in current grants, with funding from agencies such as the National Institute on Aging, the Department of Health and Human Services, and the Substance Abuse and Mental Health Services Administration. She has been principal investigator on 11 federally-funded grants and has received funding from industry, foundations, and philanthropists.
References
edit- ^ "Welcome | Department of Psychiatry and Behavioral Sciences | UC Davis Health".
- ^ Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, Ames D, Banerjee S, Burns A, Brayne C, Fox NC, Ferri CP, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Nakasujja N, Rockwood K, Samus Q, Shirai K, Singh-Manoux A, Schneider LS, Walsh S, Yao Y, Sommerlad A, Mukadam N. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31. PMID: 39096926.
- ^ Maust DT, Kim HM, Chiang C, Kales HC. Association of the Centers for Medicare & Medicaid Services' National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014. JAMA Intern Med. 2018 May 1;178(5):640-647. doi: 10.1001/jamainternmed.2018.0379. PMID: 29550856; PMCID: PMC5885206.
- ^ Maust DT, Schneider LS, Kales HC. Estimating Mortality Associated With Antipsychotics and Other Psychotropics--Reply. JAMA Psychiatry. 2015 Oct;72(10):1058. doi: 10.1001/jamapsychiatry.2015.0675. PMID: 26287522; PMCID: PMC4845912.
- ^ Weintraub D, Chiang C, Kim HM, Wilkinson J, Marras C, Stanislawski B, Mamikonyan E, Kales HC. Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. JAMA Neurol. 2016 May 1;73(5):535-41. doi: 10.1001/jamaneurol.2016.0031. PMID: 26999262; PMCID: PMC5157923.
- ^ PGitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012 Nov 21;308(19):2020-9. doi: 10.1001/jama.2012.36918. PMID: 23168825; PMCID: PMC3711645
- ^ Kales, Anthony, and Allan Rechtschaffen. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. US Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Neurological Diseases and Blindness, Neurological Information Network, 1968.
- ^ Kales A, Kales JD, Kales HC. The family business: turning sleep into dreams. Sleep Adv. 2023 Dec 27;4(1):zpad036. doi: 10.1093/sleepadvances/zpad036. PMID: 38152422; PMCID: PMC10752387.
- ^ Sirey JA, Bruce ML, Kales HC. Improving antidepressant adherence and depression outcomes in primary care: the treatment initiation and participation (TIP) program. Am J Geriatr Psychiatry. 2010 Jun;18(6):554-62. doi: 10.1097/JGP.0b013e3181cdeb7d. PMID: 20220604; PMCID: PMC3039212.
- ^ Kales HC, Gitlin LN, Lyketsos CG; Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014 Apr;62(4):762-9. doi: 10.1111/jgs.12730. Epub 2014 Mar 17. PMID: 24635665; PMCID: PMC4146407.
- ^ Kales HC, Gitlin LN, Lyketsos CG. When Less is More, but Still Not Enough: Why Focusing on Limiting Antipsychotics in People With Dementia Is the Wrong Policy Imperative. J Am Med Dir Assoc. 2019 Sep;20(9):1074-1079. doi: 10.1016/j.jamda.2019.05.022. Epub 2019 Aug 6. PMID: 31399358.
- ^ Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015 May;72(5):438-45. doi: 10.1001/jamapsychiatry.2014.3018. PMID: 25786075; PMCID: PMC4439579.
- ^ Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. Dementia prevention, intervention, and care. Lancet. 2017 Dec 16;390(10113):2673-2734. doi: 10.1016/S0140-6736(17)31363-6. Epub 2017 Jul 20. PMID: 28735855.
- ^ Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Ogunniyi A, Orgeta V, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020 Aug 8;396(10248):413-446. doi: 10.1016/S0140-6736(20)30367-6. Epub 2020 Jul 30. Erratum in: Lancet. 2023 Sep 30;402(10408):1132. doi: 10.1016/S0140-6736(23)02043-3. PMID: 32738937; PMCID: PMC7392084.
- ^ Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, Ames D, Banerjee S, Burns A, Brayne C, Fox NC, Ferri CP, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Nakasujja N, Rockwood K, Samus Q, Shirai K, Singh-Manoux A, Schneider LS, Walsh S, Yao Y, Sommerlad A, Mukadam N. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31. PMID: 39096926.